Aclysiran, an RNAi therapeutic agent targeting ACLY, treats hypercholesterolemia and atherosclerosis in ApoE -/- mice.
10.1016/j.apsb.2024.10.008
- Author:
Meijie CHEN
1
;
Peter J LITTLE
2
;
Sudong KONG
3
;
Maciej BANACH
4
;
Jianping WENG
1
;
Suowen XU
1
Author Information
1. Department of Endocrinology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
2. Department of Pharmacy, Guangzhou Xinhua University, Guangzhou 510520, China.
3. Suzhou Biosyntech Co., Ltd., Suzhou 215300, China.
4. Department of Preventive Cardiology and Lipidology, Medical University of Lodz 23 (MUL), Lodz 93-338, Poland.
- Publication Type:Journal Article
- Keywords:
ACLY;
Aclysiran;
Atherosclerosis
- From:
Acta Pharmaceutica Sinica B
2024;14(12):5505-5508
- CountryChina
- Language:English
